{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:13:30Z","timestamp":1793106810980,"version":"4.5.0"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000837","name":"University of Nottingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Optic pathway and hypothalamic glioma (OPHG) are low-grade brain tumors that arise from any part of the visual pathways frequently involving the hypothalamus. The tumors grow slowly and present with features driven by their precise anatomical site, their age at presentation and the stage of growth and development of the host neural and orbital bony tissues. Up to 50% of optic pathway glioma arise in association with Neurofibromatosis type 1 (NF1), which affects 1 in 3,000 births and is a cancer predisposition syndrome. As low-grade tumors, they almost never transform to malignant glioma yet they can threaten life when they present under two years of age. The main risks are to threaten vision loss by progressive tumor damage to optic pathways; furthermore, invasion of the hypothalamus can lead to diencephalic syndrome in infancy and hypopituitarism later in life. Progressive cognitive and behavioural dysfunction can occur, as part of NF1 syndromic features and in sporadic cases where large bulky tumors compress adjacent structures and disrupt neuro-hypothalamic pathways. Persistently progressive tumors require repeated treatments to attempt to control vision loss, other focal brain injury or endocrine dysfunction. In contrast tumors presenting later in childhood can be seen to spontaneously arrest in growth and subsequently progress after periods of stability. These patterns are influenced by NF status as well as stages of growth and development of host tissues. The past two decades has seen an expansion in our understanding and knowledge of the clinical and scientific features of these tumors, their modes of presentation, the need for careful visual and endocrine assessment. This influences the decision-making surrounding clinical management with surgery, radiotherapy, chemotherapy and most recently, the potential benefit of molecularly targeted drug therapy. This article, based upon the authors' clinical and research experience and the published literature will highlight advances in approach to diagnosis, the established role of vision loss as justification of treatments and the emerging evidence of endocrine and neurological consequences that need to be incorporated into judgements for case selection for therapy or observation. Consideration is given to the current state of biological evidence justifying current trials of new therapies, the genetic studies of the NF1 gene and the potential for new approaches to OPHG detection and treatment. The outstanding health system priorities from the perspective of children, their parents and health system commissioners or insurers are discussed.<\/jats:p>","DOI":"10.3389\/fped.2023.1038937","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T10:12:06Z","timestamp":1679652726000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["A new era for optic pathway glioma: A developmental brain tumor with life-long health consequences"],"prefix":"10.3389","volume":"11","author":[{"given":"David A.","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Aquilina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Spoudeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoong-Wei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisethe","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111790","article-title":"Optic pathway glioma in type 1 neurofibromatosis: review of its pathogenesis, diagnostic assessment, and treatment recommendations","volume":"11","author":"Cassina","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1097\/WNO.0000000000000550","article-title":"Optic pathway gliomas in neurofibromatosis type 1: an update: surveillance, treatment indications, and biomarkers of vision","volume":"37","author":"de Blank","year":"2017","journal-title":"J Neuroophthalmol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/archdischild-2018-315962","article-title":"Headsmart. Accelerating diagnosis for childhood brain tumors: an analysis of the HeadSmart UK population data","volume":"105","author":"Shanmugavadivel","year":"2020","journal-title":"Arch Dis Child"},{"key":"B4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/neuonc\/nos330","article-title":"A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the delphi method","volume":"15","author":"Walker","year":"2013","journal-title":"Neuro Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/neuonc\/noab138","article-title":"Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas","volume":"23","author":"Milde","year":"2021","journal-title":"Neuro Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1002\/ajmg.a.38308","article-title":"Growth hormone excess in children with neurofibromatosis type-1 and optic glioma","volume":"173","author":"Cambiaso","year":"2017","journal-title":"Am J Med Genet Part A"},{"key":"B7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jpeds.2015.07.001","article-title":"The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1","volume":"167","author":"Prada","year":"2015","journal-title":"J Pediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13023-018-0811-9","article-title":"Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1","volume":"13","author":"Sellmer","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fgene.2019.00115","article-title":"Commentary: identification of mutation regions on NF1 responsible for high- and low-risk development of optic pathway glioma in neurofibromatosis type I","volume":"10","author":"Anastasaki","year":"2019","journal-title":"Front Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"bjgp21X715241","DOI":"10.3399\/bjgp21X715241","article-title":"Helping GPs to diagnose children\u2019s cancer","author":"Walker","year":"2021","journal-title":"Br J Gen Pract"},{"key":"B11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1470-2045(07)70207-3","article-title":"Presentation of childhood CNS tumors: a systematic review and meta-analysis","volume":"8","author":"Wilne","year":"2007","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/adc.2009.162057","article-title":"The diagnosis of brain tumors in children: a guideline to assist healthcare professionals in the assessment of children who may have a brain tumor","volume":"95","author":"Wilne","year":"2010","journal-title":"Arch Dis Child"},{"key":"B13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/neuonc\/nov187","article-title":"A new clinical guideline from the royal college of paediatrics and child health with a national awareness campaign accelerates brain tumor diagnosis in UK children\u2013\"HeadSmart: be brain tumor aware\u201d","volume":"18","year":"2016","journal-title":"Neuro Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00381-020-04708-1","article-title":"Role, function and challenges of multidisciplinary centres for rare diseases exemplified for neurofibromatosis type 1 syndrome","volume":"36","author":"Toledano-Alhadef","year":"2020","journal-title":"Childs Nerv Syst"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/cancers14030747","article-title":"A 40-year cohort study of evolving hypothalamic dysfunction in infants and young children (&lt;3 years) with optic pathway gliomas","volume":"14","author":"Picariello","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","article-title":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u226416 years) low grade glioma - A final report","volume":"81","author":"Gnekow","year":"2017","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13052-022-01316-4","article-title":"Diencephalic syndrome in childhood, a challenging cause of failure to thrive: miniseries and literature review","volume":"48","author":"Trapani","year":"2022","journal-title":"Ital J Pediatr"},{"key":"B19","first-page":"01","article-title":"Diencephalic syndrome in child with NF-1 and hypothalamic tumor","volume":"2","author":"Pilotto","year":"2018","journal-title":"J Neurol Clin Neurosci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.clnu.2006.01.020","article-title":"ESPEN Guidelines on enteral nutrition: non-surgical oncology","volume":"25","author":"Arends","year":"2006","journal-title":"Clin Nutr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00381-021-05060-8","article-title":"Neurosurgical experience of managing optic pathway gliomas","volume":"37","author":"Hill","year":"2021","journal-title":"Childs Nerv Syst"},{"key":"B22","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3389\/fneur.2020.00766","article-title":"The visual acuity outcome and relevant factors affecting visual improvement in pediatric sporadic chiasmatic-hypothalamic glioma patients who received surgery","volume":"11","author":"Liao","year":"2020","journal-title":"Front Neurol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00381-015-2830-3","article-title":"The role of early intra-operative MRI in partial resection of optic pathway\/hypothalamic gliomas in children","volume":"31","author":"Millward","year":"2015","journal-title":"Childs Nerv Syst"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2013.8.PEDS12546","article-title":"The role of surgery in optic pathway\/hypothalamic gliomas in children: clinical article","volume":"13","author":"Goodden","year":"2014","journal-title":"J Neurosurg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3171\/2019.2.PEDS18529","article-title":"Long-term clinical and visual outcomes after surgical resection of pediatric pilocytic\/pilomyxoid optic pathway gliomas","volume":"24","author":"Hidalgo","year":"2019","journal-title":"J Neurosurg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1210\/jc.2015-2028","article-title":"Neuroendocrine morbidity after pediatric optic gliomas: a longitudinal analysis of 166 children over 30 years","volume":"100","author":"Gan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","article-title":"Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the children's oncology group","volume":"30","author":"Ater","year":"2012","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3171\/jns.1997.86.5.0747","article-title":"Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas","volume":"86","author":"Packer","year":"1997","journal-title":"J Neurosurg"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/neuonc\/nos202","article-title":"Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German speaking society of pediatric oncology and hematology","volume":"14","author":"Gnekow","year":"2012","journal-title":"Neuro Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/pbc.25697","article-title":"Carboplatin rechallenge after hypersensitivity reactions in pediatric patients with low-grade glioma","volume":"63","author":"Shah","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/neuonc\/not154","article-title":"Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas\u2013a pediatric brain tumor consortium study","volume":"16","author":"Gururangan","year":"2014","journal-title":"Neuro Oncol"},{"key":"B32","first-page":"6731","article-title":"Vincristine-induced blindness: a case report and review of literature","volume":"34","author":"Adhikari","year":"2014","journal-title":"Anticancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ijc.29711","article-title":"Single agent carboplatin for pediatric low-grade glioma: a retrospective analysis shows equivalent efficacy to multiagent chemotherapy","volume":"138","author":"Dodgshun","year":"2016","journal-title":"Int J Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for chemotherapy-na\u00efve children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study","volume":"34","author":"Lassaletta","year":"2016","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00066-003-9104-9","article-title":"Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part I: treatment modalities of radiation therapy","volume":"179","author":"Kortmann","year":"2003","journal-title":"Strahlenther Onkol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.14694\/EdBook_AM.2014.34.e44","article-title":"Predisposition to pediatric and hematologic cancers: a moving target","volume":"34","author":"Malkin","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ijrobp.2019.01.078","article-title":"Outcomes following proton therapy for pediatric low-grade glioma","volume":"104","author":"Indelicato","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J Med Genet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.ijrobp.2006.01.038","article-title":"Radiation-induced moyamoya syndrome","volume":"65","author":"Desai","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B40","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.ijrobp.2018.03.027","article-title":"Risk of radiation vasculopathy and stroke in pediatric patients treated with proton therapy for brain and skull base tumors","volume":"101","author":"Hall","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1200\/JCO.19.01270","article-title":"Revisiting the role of radiation therapy for pediatric low-grade glioma","volume":"37","author":"Bitterman","year":"2019","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1259\/bjr\/65246351","article-title":"Radiological classification of optic pathway gliomas: experience of a modified functional classification system","volume":"81","author":"Taylor","year":"2008","journal-title":"Br J Radiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1212\/WNL.0000000000003402","article-title":"Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1","volume":"87","author":"Avery","year":"2016","journal-title":"Neurology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/neuonc\/not068","article-title":"Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1","volume":"15","author":"de Blank","year":"2013","journal-title":"Neuro-Oncology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e0258548","DOI":"10.1371\/journal.pone.0258548","article-title":"Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: a systematic review","volume":"16","author":"Bennebroek","year":"2021","journal-title":"Plos One"},{"key":"B46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/neuonc\/noaa153","article-title":"NF1 Optic pathway glioma: analyzing risk factors for visual outcome and indications to treat","volume":"23","author":"Azizi","year":"2021","journal-title":"Neuro Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/neuonc\/nos076","article-title":"Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis","volume":"14","author":"Fisher","year":"2012","journal-title":"Neuro Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0212107","DOI":"10.1371\/journal.pone.0212107","article-title":"Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy-analysis of a French pediatric historical cohort","volume":"14","author":"Rakotonjanahary","year":"2019","journal-title":"PLoS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1001\/jamaophthalmol.2013.571","article-title":"Visual function and optic pathway glioma: a critical response","volume":"131","author":"Gutmann","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1001\/jamaophthalmol.2013.5819","article-title":"Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab","volume":"132","author":"Avery","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"iv56-","DOI":"10.1093\/neuonc\/nox083.233","article-title":"Developing risk-based selection criteria for the next siop trial of \u201csight-saving therapy\u201d for children with nf1-associated visual pathway glioma (NF1-VPG)-a qualitative analysis of a consensus survey","volume":"19","author":"Walker","year":"2017","journal-title":"Neuro-oncology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.7150\/jca.33463","article-title":"Natural history of pediatric low-grade glioma disease - first multi-state model analysis","volume":"10","author":"Goebel","year":"2019","journal-title":"J Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/nop\/npaa031","article-title":"SIOPE NF1 OPG Nottingham U, workshop. Regarding \u201cneuro-oncology practice clinical debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma\u201d","volume":"7","author":"Walker","year":"2020","journal-title":"Neurooncol Pract"},{"key":"B54","year":""},{"key":"B55","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S1470-2045(20)30022-X","article-title":"Sustainable care for children with cancer: a lancet oncology commission","volume":"21","author":"Atun","year":"2020","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3399\/bjgp21X715241","article-title":"Helping GPs to diagnose children's cancer","volume":"71","author":"Walker","year":"2021","journal-title":"Br J Gen Pract"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-320119","article-title":"Temporal trends in the epidemiology of childhood severe visual impairment and blindness in the UK","author":"Teoh","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"B58","year":""},{"key":"B59","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1007\/s00520-021-06193-x","article-title":"Unmet support needs in teenage and young adult childhood brain tumor survivors and their caregivers: \u201cit\u2019s all the aftermath, and then you\u2019re forgotten about\u201d","volume":"29","author":"Nicklin","year":"2021","journal-title":"Support Care Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/14728222.2018.1465931","article-title":"Emerging therapeutic targets for neurofibromatosis type 1","volume":"22","author":"Walker","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/neuonc\/now282","article-title":"A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a pediatric brain tumor consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a pediatric brain tumor consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: tRAM-01","volume":"19","author":"Perreault","year":"2019","journal-title":"BMC Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00381-020-04724-1","article-title":"A systematic review of ongoing clinical trials in optic pathway gliomas","volume":"36","author":"Hill","year":"2020","journal-title":"Child's Nerv Syst"},{"key":"B66","year":""},{"key":"B67","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","article-title":"Pediatric low-grade glioma in the era of molecular diagnostics","volume":"8","author":"Ryall","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"B68","doi-asserted-by":"publisher","first-page":"i89","DOI":"10.1093\/neuonc\/noac079.325","article-title":"LGG-09. A nationwide service evaluation of safety, radiologic and visual outcome refining bevacizumab-based treatments in children with progressive low-grade glioma","volume":"24","author":"Green","year":"2022","journal-title":"Neuro-Oncology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/brain\/awv366","article-title":"Nerve growth factor improves visual loss in childhood optic gliomas: a randomized, double-blind, phase II clinical trial","volume":"139","author":"Falsini","year":"2016","journal-title":"Brain"},{"key":"B70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fneur.2020.601286","article-title":"Stem cell therapy for pediatric traumatic brain injury","volume":"2020","author":"Lengel","year":"2020","journal-title":"Front Neurol"},{"key":"B71","year":""},{"key":"B72","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fonc.2022.982914","article-title":"Childhood brain tumors: it is the child\u2019s brain that really matters","volume":"2022","author":"Walker","year":"2022","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ejpn.2016.10.010","article-title":"Where are the opportunities for an earlier diagnosis of primary intracranial tumors in children and young adults?","volume":"21","author":"Chu","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1177\/00258172221099077","article-title":"The costs of avoidable injury from childhood cancer: litigate or mediate?","author":"Walker","year":"2022","journal-title":"Medico Legal"},{"key":"B75","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1212\/01.wnl.0000435745.95155.b8","article-title":"Functional outcome measures for NF1-associated optic pathway glioma clinical trials","volume":"81","author":"Fisher","year":"2013","journal-title":"Neurology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"vdaa090","DOI":"10.1093\/noajnl\/vdaa090","article-title":"Predicting pediatric optic pathway glioma progression using advanced magnetic resonance image analysis and machine learning","volume":"2","author":"Pisapia","year":"2020","journal-title":"Neurooncol Adv"},{"key":"B77","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/neuonc\/nox141","article-title":"Pediatric low-grade gliomas: next biologically driven steps","volume":"20","author":"Jones","year":"2018","journal-title":"Neuro Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nrc1633","article-title":"Childhood solid tumors: a developmental disorder","volume":"5","author":"Scotting","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/neuonc\/noq092","article-title":"A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702)","volume":"12","author":"Stokland","year":"2010","journal-title":"Neuro Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03580-6","article-title":"NF1 Mutation drives neuronal activity-dependent initiation of optic glioma","volume":"594","author":"Pan","year":"2021","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2007.10.007","article-title":"Atopic dysfunction and risk of central nervous system tumors in children","volume":"44","author":"Harding","year":"2008","journal-title":"Eur J Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10552-013-0171-7","article-title":"Allergy and brain tumors in the INTERPHONE study: pooled results from Australia, Canada, France, Israel, and New Zealand","volume":"24","author":"Turner","year":"2013","journal-title":"Cancer Causes Control"},{"key":"B83","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/aje\/kwm203","article-title":"Allergic conditions and brain tumor risk","volume":"166","author":"Wigertz","year":"2007","journal-title":"Am J Epidemiol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/brain\/awg016","article-title":"Prognostic factors of CNS tumors in neurofibromatosis 1 (NF1): a retrospective study of 104 patients","volume":"126","author":"Guillamo","year":"2002","journal-title":"Brain"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1038937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T10:12:13Z","timestamp":1679652733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1038937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":84,"alternative-id":["10.3389\/fped.2023.1038937"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1038937","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"article-number":"1038937"}}